News

Patients across the country continue to feel the impact of critical prescription drug shortages. As formulary managers understand, an integrated approach to solving shortages, involving all supply chain stakeholders, can have a profound effect on mitigating the impact of shortages on patients.

When vaccines eradicate illnesses (eg, smallpox), life is grand. However, when eradication is impossible (eg, pneumococcus), what is the goal of vaccination? The most essential vaccine function is to reduce the number and/or severity of infections.

The Middle East respiratory syndrome (MERS) is an infectious viral disease with about 30% mortality caused by viral pneumonia and associated lung damage. The etiologic agent of MERS, MERS-CoV, is a member of the coronavirus family. Coronaviruses are responsible for a variety of pathologic effects in a broad spectrum of vertebrates including the virus currently responsible for epidemic piglet deaths in hog farms in the United States. The pathogenicity of MERS is due, in part, to the innate immune deficiency state that results from inhibition of a first responder to viral infection, interferon (IFN).

The US Preventive Services Task Force (USPSTF) is taking a stand on trying to reduce the incidence of hepatitis B (HBV) by recommending that individuals who are at high risk of infection should be screened.

Injecting botulinum toxin injection into the epicardial fat pads prevented recurrences of atrial tachyarrhythmia in the postoperative period in patients with prior paroxysmal atrial fibrillation (PAF) undergoing coronary artery bypass grafting (CABG) surgery, according to results of a study presented at the Heart Rhythm Society meeting in San Francisco.

Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common epidermal growth factor receptor (EGFR) mutation (exon 19 deletion) lived longer if treated with first-line afatinib (Gilotrif) compared to chemotherapy, according to data presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), in Chicago.

Pirfenidone (Esbriet), an oral antifibrotic therapy, was able to reduce progression of idiopathic pulmonary fibrosis (IPF) and reduce the risk of mortality, according to phase 3 trial results presented at the American Thoracic Society International Conference in San Diego.